N/A N=53 Occult Paroxysmal Atrial Fibrillation in Non-Cryptogenic Ischemic Stroke
Ischemic Stroke
Primary: Incidence of Paroxysmal Atrial Fibrillation (AF) in Ischemic Stroke Patients — 6 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=272 A Study for Treatment of Paroxysmal Atrial Fibrillation (PAF) by Pulsed Field Ablation (PFA) System With Irreversible Electroporation (IRE)
Atrial Fibrillation
Primary: Number of Participants With Primary Adverse Events (PAEs) — 0; 0; 0 Participants
N/A N=149 A Study For Treatment Of Paroxysmal Atrial Fibrillation (PAF) With The THERMOCOOL SMARTTOUCH SF Catheter and TRUPULSE Generator
Atrial Fibrillation
Primary: Percentage of Participants With Primary Adverse Events (PAEs) — 0.0; 0.0; 1.5; 1.5 percentage of participants
N/A N=109 Effect of Treatment of Sleep Apnea in Patients With Paroxysmal Atrial Fibrillation
Sleep Disordered Breathing · Sleep Apnea · Paroxysmal Atrial Fibrillation
Primary: Change in AF Burden — 5.6; 5.0; 4.1; 4.3 percentage of time in AF — p=0.520
N/A N=404 Boston Scientific's Cryoballoon in the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Primary: Percentage of Participants With Freedom From Primary Safety Events at 12 Months Post-procedure (Acute and Chronic Events) Using the Boston Scientific Cardiac…
N/A N=177 A Study For Treatment of Paroxysmal Atrial Fibrillation (PAF) With the OMNYPULSE Catheter and the TRUPULSE Generator
Atrial Fibrillation
Primary: Percentage of Participants With Primary Adverse Events (PAEs) — 0; 0; 0; 0 Percentage of participants
N/A N=25 Atrial Fibrillation Recurrence in Sleep Apnea
Sleep Apnea · Atrial Fibrillation
Primary: Number of Subjects Who Had Atrial Fibrillation Recurrence at 1 Year — 3; 3 participants
N/A N=324 Irrigated Ablation System Evaluation for Atrial Fibrillation (AF)
Paroxysmal Atrial Fibrillation
Primary: Confirmation of Entrance Block in the Pulmonary Veins — 159; 157 participants
Phase 1 N=48 A Trial to Determine the Safety, Pharmacokinetics, and Efficacy of OPC-108459 Administered as a Single Intravenous Dose to Patients With Paroxysmal or Persistent Atrial Fibrillation (AF)
Atrial Fibrillation
Primary: Subjects Achieving Normal Sinus Rhythm (NSR) in Patients With Paroxysmal AF — 0; 2; 0; 0 Participants
N/A N=80 The FARAPULSE PersAFOne III Trial for the Treatment of Persistent Atrial Fibrillation
Persistent Atrial Fibrillation
Primary: Primary Safety Endpoint: Composite Safety Endpoint (CSE) Defined as the Incidence of the Following Early-onset and Late-onset Serious Adverse Events (SAEs) Which Are…
Phase 4 N=55 Ablation of the Pulmonary Veins for Paroxysmal Afib
Paroxysmal Atrial Fibrillation
Primary: Number of Participants With Successful Pulmonary Vein Isolation — 53 participants
N/A N=15 A Single Arm Pilot Study of Pulsed Field Ablation in the Treatment of Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Primary: Occurence of Device-or Procedure-related Early and Late-onset of Serious Adverse Events — 0 Participants
N/A N=669 A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation
Persistent Atrial Fibrillation
Primary: Primary Safety Endpoint (PSE): Event Rate of Safety Events Post Procedure — 2.3; 2.4 Percentage of participants
Phase 3 N=210 Tailored Treatment of Permanent Atrial Fibrillation
Atrial Fibrillation
Primary: Chronic Effectiveness — 56; 26 percentage of participants with success — p=<0.0001
Phase 3 N=353 HeartLight Ablation in Patients With Paroxysmal Atrial Fibrillation (PAF)
Paroxysmal Atrial Fibrillation
Primary: Number of Participants That Meeting the Efficacy Success Criteria as Described in the Outcome Measure Description — 102; 103 Successful Participants
N/A N=24 Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study
Persistent Atrial Fibrillation · Longstanding Persistent Atrial Fibrillation
Primary: Primary Safety Endpoint — 0; 0; 4.2; 0 percentage of participants
N/A N=381 Safety and Effectiveness of STSF Catheter Evaluated for Treating Symptomatic Persistent Atrial Fibrillation (PsAF)
Atrial Fibrillation
Primary: Primary Safety Endpoint - Percentage of Participants With Any PAE Within 7 Days — 4.7 Percentage of participants
Phase 3 N=81 Clinical Study of the CardioFocus Endoscopic Ablation System for the Treatment of Symptomatic AF
Paroxysmal Atrial Fibrillation
Primary: Chronic Effectiveness in Treating PAF as Demonstrated by no AF Recurrences After the Blanking Period and During the 12-month Follow-up Period. — 42 Successful participants
Phase 3 N=172 THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation
Heart Diseases · Arrhythmia · Atrial Fibrillation
Primary: The Rate of Subjects Who Were Free From Documented Symptomatic Atrial Fibrillation (AF), Atrial Tachycardia (AT), or Atrial Flutter (AFL) Episodes Through 12-month…
N/A N=607 The FARAPULSE ADVENT PIVOTAL Trial PFA System vs SOC Ablation for Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Primary: Composite Safety Endpoint;Proportion of MITT Subjects With One or More of the Specified Device or Procedure Related SAEs — 6; 4 Participants
N/A N=55 Hybrid Ablation Plus Medical Therapy for Persistent Atrial Fibrillation
Persistent Atrial Fibrillation
Primary: Atrial Fibrillation (AF) Burden Defined as the Mean Amount of Time Spent in AF Over a Pre-specified Period of Time (Excluding Short AF Episodes of ≤30 Seconds) by the…
Phase 3 N=397 Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation
Atrial Fibrillation
Primary: Number of Participants With Any Primary Adverse Events (PAE) That Occurred Within 7 Days Following Atrial Fibrillation (AF) Ablation Procedure Using HELIOSTAR Catheter…
Phase 2 N=186 REVOLUTION (WFCC-133) - Treatment of Paroxysmal Atrial Fibrillation
Paroxysmal Atrial Fibrillation
Primary: The Incidence of Early Onset Primary Adverse Events — 5.5 percentage of participants
Phase 4 N=102 Electrophysiologically Guided PAcing Site Selection Study
Sinus Arrhythmia · Atrial Fibrillation
Primary: Number of Patients With Persistent Atrial Fibrillation (AF) After a Mean Follow-up of 15±7 Months: Comparison Between IAS and RAA Pacing in the Study Group — 2; 2; 9; 2…
N/A N=421 Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF
Atrial Fibrillation
Primary: Safety: Number of Participants With at Least One Primary Safety Event — 1; 1 Participants
Phase 4 N=59 Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Atrial Fibrillation
Primary: Number of Days on Anticoagulation — 24.9 days
Phase 3 N=127 First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment (The RAAFT Study)
Atrial Fibrillation
Primary: Number of Participants With Recurrence of Atrial Tachyarrhythmia — 36; 44 Participants — p=0.0016
N/A N=365 ABLATE Post Approval Study - Synergy Ablation Lesions for Non-Paroxysmal Atrial Fibrillation
Persistent Atrial Fibrillation · Longstanding Persistent Atrial Fibrillation
Primary: The Number of Participants Free From Atrial Fibrillation (AF), Atrial Flutter or Atrial Tachycardia While Off Class I and Class III Antiarrhythmic Drugs for at Least 4…
Phase 4 N=83 Selective Complex Fractionated Atrial Electrograms (CFAE) Targeting for Atrial Fibrillation
Atrial Fibrillation
Primary: Proportion of Subjects Who Were Free From Atrial Arrhythmia at One Year. — 10; 18; 29; 20 participants — p=0.048
Phase 4 N=24 Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit
Atrial Fibrillation
Primary: Conversion From Atrial Fibrillation to Sinus Rhythm — 8; 5 participants